Optimum Investment Advisors Bristol Myers Squibb CO Transaction History

Optimum Investment Advisors

$220 Million
Q2 2024

A detailed history of Optimum Investment Advisors transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Optimum Investment Advisors holds 15,925 shares of BMY stock, worth $859,313. This represents 0.3% of its overall portfolio holdings.

Number of Shares

15,925

Previous 16,363 2.68%

Holding current value

$859,313

Previous $887,000 25.48%

% of portfolio

0.3%

Previous 0.41%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 12, 2024	SELL	$40.25 - $52.99 $17,629 - $23,209	-438 Reduced 2.68%	15,925 $661,000
Q1 2024 Apr 11, 2024	SELL	$47.98 - $54.4 $31,091 - $35,251	-648 Reduced 3.81%	16,363 $887,000
Q4 2023 Jan 08, 2024	SELL	$48.48 - $57.85 $116,255 - $138,724	-2,398 Reduced 12.36%	17,011 $872,000
Q3 2023 Oct 13, 2023	SELL	$57.89 - $64.73 $72,767 - $81,365	-1,257 Reduced 6.08%	19,409 $1.13 Million
Q2 2023 Aug 03, 2023	BUY	$63.71 - $70.74 $82,950 - $92,103	1,302 Added 6.72%	20,666 $1.32 Million
Q1 2023 May 03, 2023	SELL	$65.71 - $74.53 $86,408 - $98,006	-1,315 Reduced 6.36%	19,364 $1.34 Million
Q4 2022 Jan 05, 2023	SELL	$68.48 - $81.09 $97,515 - $115,472	-1,424 Reduced 6.44%	20,679 $0
Q3 2022 Oct 24, 2022	SELL	$0.13 - $76.84 $21 - $12,985	-169 Reduced 0.76%	22,103 $1.57 Million
Q2 2022 Jul 12, 2022	SELL	$72.62 - $79.98 $71,893 - $79,180	-990 Reduced 4.26%	22,272 $1.72 Million
Q1 2022 Apr 08, 2022	SELL	$61.48 - $73.72 $24,592 - $29,488	-400 Reduced 1.69%	23,262 $1.7 Million
Q4 2021 Mar 17, 2022	SELL	$53.63 - $62.52 $128,336 - $149,610	-2,393 Reduced 9.18%	23,662 $1.48 Million
Q3 2021 Oct 22, 2021	SELL	$59.17 - $69.31 $678,857 - $795,193	-11,473 Reduced 30.57%	26,055 $1.54 Million
Q3 2021 Oct 12, 2021	SELL	$59.17 - $69.31 $14,792 - $17,327	-250 Reduced 0.66%	37,528 $2.51 Million
Q2 2021 Aug 02, 2021	SELL	$61.91 - $67.42 $215,880 - $235,093	-3,487 Reduced 8.45%	37,778 $2.52 Million
Q1 2021 Apr 15, 2021	SELL	$59.34 - $66.74 $94,944 - $106,783	-1,600 Reduced 3.73%	41,265 $2.61 Million
Q4 2020 Jan 21, 2021	SELL	$57.74 - $65.43 $98,158 - $111,231	-1,700 Reduced 3.81%	42,865 $2.66 Million
Q3 2020 Oct 06, 2020	SELL	$57.43 - $63.64 $328,786 - $364,339	-5,725 Reduced 11.38%	44,565 $2.69 Million
Q2 2020 Jul 16, 2020	BUY	$54.82 - $64.09 $21,928 - $25,636	400 Added 0.8%	50,290 $2.96 Million
Q1 2020 Apr 21, 2020	SELL	$46.4 - $67.43 $121,521 - $176,599	-2,619 Reduced 4.99%	49,890 $2.78 Million
Q4 2019 Jan 22, 2020	BUY	$49.21 - $64.19 $143,939 - $187,755	2,925 Added 5.9%	52,509 $3.37 Million
Q3 2019 Oct 17, 2019	BUY	$42.77 - $50.71 $53,462 - $63,387	1,250 Added 2.59%	49,584 $2.51 Million
Q2 2019 Jul 29, 2019	SELL	$44.62 - $49.34 $156,839 - $173,430	-3,515 Reduced 6.78%	48,334 $2.19 Million
Q1 2019 May 03, 2019	SELL	$45.12 - $53.8 $72,192 - $86,080	-1,600 Reduced 2.99%	51,849 $2.47 Million
Q4 2018 Feb 04, 2019	SELL	$48.76 - $63.23 $74,602 - $96,741	-1,530 Reduced 2.78%	53,449 $2.78 Million
Q3 2018 Oct 05, 2018	SELL	$55.19 - $62.25 $20,696 - $23,343	-375 Reduced 0.68%	54,979 $3.41 Million
Q2 2018 Oct 05, 2018	SELL	$50.53 - $62.98 $83,627 - $104,231	-1,655 Reduced 2.9%	55,354 $3.06 Million
Q1 2018 May 09, 2018	SELL	$59.92 - $68.98 $5,992 - $6,898	-100 Reduced 0.18%	57,009 $3.61 Million
Q4 2017 Jan 16, 2018	SELL	$59.94 - $65.35 $45,554 - $49,665	-760 Reduced 1.31%	57,109 $3.5 Million
Q3 2017 Nov 21, 2017	BUY	$55.23 - $63.74 $41,422 - $47,805	750 Added 1.31%	57,869 $3.69 Million
Q2 2017 Aug 14, 2017	BUY	N/A	57,119	57,119 $3.18 Million

Others Institutions Holding BMY

# of Institutions

2,407

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $115B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Optimum Investment Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Optimum Investment Advisors with notifications on news.

Account

Optimum Investment Advisors Bristol Myers Squibb CO Transaction History